Kezar Life Sciences Inc Stock

$0.56

3.52% day before yesterday

Nasdaq, Sep 06, 10:00 pm CET

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Kezar Life Sciences Inc Stock price

$0.56

-2.82 83.45% 5Y

Nasdaq, Closing price Fri, Sep 06 2024

-0.02 3.52%

ISIN

US49372L1008

Symbol

KZR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$40.82m
Enterprise Value	$-105.75m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	1.33
EV/Sales (TTM) EV/Sales	-15.11
P/S ratio (TTM) P/S ratio	5.83
P/B ratio (TTM) P/B ratio	0.27
Revenue (TTM) Revenue	$7.00m
EBIT (operating result TTM) EBIT	$-99.54m
Free Cash Flow (TTM) Free Cash Flow	$-79.22m
Cash position	$164.18m
EPS (TTM) EPS	$-1.35
P/E forward	negative
P/S forward	17.01
EV/Sales forward	negative
Short interest	1.20%

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Kezar Life Sciences Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Kezar Life Sciences Inc forecast:

3x Buy

50%

3x Hold

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Kezar Life Sciences Inc forecast:

Buy

50%

Hold

50%

Analyst Estimates with Stock Price Targets

Financial data from Kezar Life Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	7 7	- 100%
- Direct Costs	1.08 1.08	11% 11% 15%
Gross Profit	5.92 5.92	- 85%
- Selling and Administrative Expenses	25 25	15% 15% 350%
- Research and Development Expense	80 80	17% 17% 1,141%
EBITDA	-98 -98	10% 10% -1,407%
- Depreciation and Amortization	1.08 1.08	- 15%
EBIT (Operating Income) EBIT	-100 -100	10% 10% -1,422%
Net Profit	-99 -99	19% 19% -1,408%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Kezar Life Sciences Inc Stock News

Neutral

Business Wire

●

3 days ago

Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on We...

Neutral

Business Wire

●

25 days ago

Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “We are thrilled to announce completion of enrollment to...

Neutral

Business Wire

●

about 2 months ago

Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 72,000 shares of its...

More Kezar Life Sciences Inc News

Company Profile

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

Head office	United States
CEO	Christopher Kirk
Employees	58
Founded	2015
Website	www.kezarlifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now